Recerca > Càncer

Grup de recerca de biomarcadors en càncer (GReBiC)

Nombre de publicacions
495
Cercador de publicacions
  • Griguolo, G; Serna, G; Pascual, T; Fasani, R; Chic, N; Pare, L; Pernas, S; Munoz, M; Oliveira, M; Vidal, M; Cussac, AL; Cortes, J; Galvan, P; Bermejo, B; Martinez, N; Lopez, R; Morales, S; Villagrasa, P; Prat, A; Nuciforo, P

    Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)

    ANNALS OF ONCOLOGY 31 19-19. .

    [doi:10.1016/j.annonc.2020.03.144]

  • Porcel, JM; Torres, M; Pardina, M; Civit, C; Salud, A; Bielsa, S

    Predictors of Indwelling Pleural Catheter Removal and Infection A Single-center Experience With 336 Procedures

    JOURNAL OF BRONCHOLOGY & INTERVENTIONAL PULMONOLOGY 27 86-94. .

    [doi:10.1097/LBR.0000000000000632]

  • Porcel, JM; Ferreiro, L; Rumi, L; Espino-Paisan, E; Civit, C; Pardina, M; Schoenenberger-Arnaiz, JA; Valdes, L; Bielsa, S

    Two vs. three weeks of treatment with amoxicillin-clavulanate for stabilized community-acquired complicated parapneumonic effusions. A preliminary non-inferiority, double-blind, randomized, controlled trial

    Pleura and Peritoneum 5 20190027-20190027. .

    [doi:10.1515/pp-2019-0027]

  • Wang, E; Sorolla, MA; Krishnan PDG; Sorolla, A

    From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds.

    Biomolecules 10 -. .

    [doi:10.3390/biom10020248]

  • Martin, M; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Ciruelos, E; Munoz, M; Bermejo, B; Margeli, M; Turner, N; Casas, M; Anton, A; Csoszi, T; Corsaro, M; Murillo, L; Morales, S; Alba, E; Bartlett, CH; Koehler, M; Guerrero, A; Kahan, Z; Gil-Gil, M

    Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)

    CANCER RESEARCH 80 -. .

    [doi:10.1158/1538-7445.SABCS19-GS2-07]

  • Braso-Maristany, F; Griguolo, G; Pascual, T; Pare, L; Nuciforo, P; Llombart-Cussac, A; Bermejo, B; Oliveira, M; Morales, S; Martinez, N; Vidal, M; Adamo, B; Martinez, O; Pernas, S; Lopez, R; Muñoz M; Chic, N; Galvan, P; Garau, I; Manso, L; Alarcon, J; Martinez, E; Gregorio, S; Gomis, RR; Villagrasa, P; Cortes, J; Ciruelos, E; Prat, A

    Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

    Nature Communications 11 385-385. .

    [doi:10.1038/s41467-019-14111-3]

  • Tur Martínez J; Escartin, A; Pardina, M; Olsina, JJ

    Celiacomesenteric trunk: A rare vascular variant

    CIRUGIA ESPANOLA 98 46-46. .

    [doi:10.1016/j.ciresp.2019.03.007]

  • Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E

    Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.

    Clinical Colorectal Cancer 19 110-116. .

    [doi:10.1016/j.clcc.2020.02.014]

  • Quintela-Fandino, M; Morales, S; Cortes-Salgado, A; Manso, L; Apala, JV; Munoz, M; Cudos, AG; Fortuny, JS; Gion, M; Lopez-Alonso, A; Cortes, J; Guerra, J; Malon, D; Caleiras, E; Mulero, F; Mouron, S

    Randomized Phase O/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

    CLINICAL CANCER RESEARCH 26 35-45. .

    [doi:10.1158/1078-0432.CCR-19-2023]

  • Prat, A; Pascual, T; De Angelis, C; Gutierrez, C; Llombart-Cussac, A; Wang, T; Cortes, J; Rexer, B; Pare, L; Forero, A; Wolff, AC; Morales, S; Adamo, B; Braso-Maristany, F; Vidal, M; Veeraraghavan, J; Krop, I; Galvan, P; Pavlick, AC; Bermejo, B; Izquierdo, M; Rodrik-Outmezguine, V; Reis-Filho, JS; Hilsenbeck, SG; Oliveira, M; Dieci, MV; Griguolo, G; Fasani, R; Nuciforo, P; Parker, JS; Conte, P; Schiff, R; Guarneri, V; Osborne, CK; Rimawi, MF

    HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 112 46-54. .

    [doi:10.1093/jnci/djz042]

  • Manso L; Hernando C; Galán M; Oliveira M; Cabrera MA; Bratos R; Rodríguez CA; Ruiz-Borrego M; Blanch S; Llombart-Cussac A; Delgado-Mingorance JI; Álvarez-Busto I; Gallegos I; González-Cortijo L; Morales S; Aguirre E; Hernando BA; Ballesteros A; Alés-Martínez JE; Reboredo C; Oltra A; González-Cao M; Santisteban M; Malón D; Echeverría I; García-Garre E; Vega E; Servitja S; Andrés R; Robles CE; López R; Galve E; Echarri MJ; Legeren M; Moreno F

    Palbociclib combined with endocrine therapy in heavily pretreated HR(+)/HER2(-) advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).

    BREAST 54 286-292. .

    [doi:10.1016/j.breast.2020.11.005]

  • Porcel JM

    Natriuretic peptides in pleural effusions: Beyond a diagnosis of heart failure.

    RESPIROLOGY 25 1021-1022. .

    [doi:10.1111/resp.13847]